Prostate cancer is the second most common cancer and the leading cause of cancer-related deaths in men.
Patients with metastatic castration-resistant prostate cancer (mCRPC) with diffuse bone metastases have limited treatment options due to severe hematological toxicity risks.
This study evaluates the safety and efficacy of [
